Takeda Expanding ALS Investments with Aquinnah Partnership

Takeda Pharmaceuticals, the largest pharmaceutical company in Japan, is expanding its presence in the ALS space with two new partnerships: a new $5M investment in Aquinnah Pharmaceuticals, aCambridge, MA, based startup company that is developing small molecule therapeutics that prevent TDP-43 protein aggregation and stress granule formation (see Nov 2015 news), as well as a 3-year research collaboration with the University College London, to identify genes and signaling pathways that regulate neuronal health and survival in ALS, Huntington’s disease and Parkinson’s disease.

Click here to read more.

disease-als topic-preclinical topic-randd
Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail